Patterns of brain glucose metabolism induced by phosphodiesterase 10a inhibitors in the mouse: A potential translational biomarker

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 1, 2011, Pages 210-217

  Dedeurwaerdere, Stefanie ^a   Wintmolders, Cindy ^b   Vanhoof, Greet ^b   Langlois, Xavier ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6,7 DIMETHOXY 4 [3 (2 QUINOXALINLOXY) 1 PYRROLIDINYL]QUINAZOLINE; BIOLOGICAL MARKER; DEOXYGLUCOSE; DOPAMINE 1 RECEPTOR; HALOPERIDOL; PAPAVERINE; PHOSPHODIESTERASE 10A INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PQ 10; UNCLASSIFIED DRUG;

ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; BRAIN METABOLISM; CONTROLLED STUDY; DOSE RESPONSE; GLOBUS PALLIDUS; GLUCOSE METABOLISM; HABENULA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; BENZAZEPINES; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; DENSITOMETRY; DEOXYGLUCOSE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HALOPERIDOL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PAPAVERINE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROTEIN MODIFICATION, TRANSLATIONAL;

EID: 80053141755     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.182766     Document Type: Article

References (30)

1. Buchsbaum MS, Haznedar M, Newmark RE, Chu KW, Dusi N, Entis JJ, Goldstein KE, Goodman CR, Gupta A, Hazlett E, et al. (2009) FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia. Schizophrenia Res 114:161-171.
2. Celen S, Koole M, De Angelis M, Sannen I, Chitneni SK, Alcazar J, Dedeurwaerdere S, Moechars D, Schmidt M, Verbruggen A, et al. (2010) Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J Nucl Med 51:1584-1591.
3. Dedeurwaerdere S, Wintmolders C, Straetemans R, Pemberton D, and Langlois X (2011) Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. Psychopharmacology (Berl) 214:505-514.
4. Duncan GE, Leipzig JN, Mailman RB, and Lieberman JA (1998) Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 812:65-75. (Pubitemid 29005332)
5. Ellison G (1994) Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res Brain Res Rev 19:223-239.
6. Fujishige K, Kotera J, and Omori K (1999) Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 266:1118-1127. (Pubitemid 30010131)
7. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, et al. (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331:574-590.
8. Hauber W (1998) Involvement of basal ganglia transmitter systems in movement initiation. Prog Neurobiol 56:507-540.
9. Hikosaka O (2010) The habenula: from stress evasion to value-based decision-making. Nat Rev Neurosci 11:503-513.
10. 14C]-2-deoxyglucose uptake in freely moving rats. Brain Res 921:260-263.
11. Kimura M, Satoh T, and Matsumoto N (2007) What does the habenula tell dopamine neurons? Nat Neurosci 10:677-678. (Pubitemid 46828498)
12. Kita H (2007) Globus pallidus external segment, in Progress in Brain Research Gaba and the Basal Ganglia-From Molecules to Systems (James MT ed) pp 111-133, Elsevier, New York.
13. MacIntosh BJ, Pattinson KT, Gallichan D, Ahmad I, Miller KL, Feinberg DA, Wise RG, and Jezzard P (2008) Measuring the effects of remifentanil on cerebral blood flow and arterial arrival time using 3D GRASE MRI with pulsed arterial spin labelling. J Cereb Blood Flow Metab 28:1514-1522.
14. McKie S, Del-Ben C, Elliott R, Williams S, Del Vai N, Anderson I, and Deakin JF (2005) Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology 180:680-686. (Pubitemid 41317864)
15. Menniti FS, Chappie TA, Humphrey JM, and Schmidt CJ (2007) Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 8:54-59. (Pubitemid 46438266)
16. Murphy SE and Mackay CE (2010) Using MRI to measure drug action: caveats and new directions. J Psychopharmacol doi: 10.1177/0269881110372547.
17. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, and Kapur S (2005) Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31:1854-1863.
18. Paxinos G and Franklin KB (2001) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA.
19. Pizzolato G, Soncrant TT, and Rapoport SI (1984) Haloperidol and cerebral metabolism in the conscious rat: relation to pharmacokinetics. J Neurochem 43:724-732. (Pubitemid 14065455)
20. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, et al. (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681-690. (Pubitemid 351574819)
21. Schmidt ME, Andrews RD, Van der Ark P, Brown T, Mannaert E, Steckler T, De Hoon J, and Van Laere K (2010) Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology (Berl) 208:109-119.
22. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, et al. (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113-126. (Pubitemid 37088176)
23. Siuciak JA (2008) The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 22:983-993.
24. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, and Schmidt CJ (2006a) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51:386-396. (Pubitemid 44061894)
25. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, et al. (2006b) Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 51:374-385. (Pubitemid 44061880)
26. Siuciak JA, McCarthy SA, Chapin DS, Martin AN, Harms JF, and Schmidt CJ (2008) Behavioral characterization of mice deficient in the phosphodiesterase- 10A (PDE10A) enzyme on a C57/Bl6N congenic background. Neuropharmacology 54: 417-427.
27. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, and Shinohara M (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897-916. (Pubitemid 8098854)
28. Torremans A, Ahnaou A, Van Hemelrijck A, Straetemans R, Geys H, Vanhoof G, Meert TF, and Drinkenburg WH (2010) Effects of phosphodiesterase 10 inhibition on striatal cyclic AMP and peripheral physiology in rats. Acta Neurobiol Exp (Wars) 70:13-19.
29. Warnock G, Moechars D, Langlois X, and Steckler T (2009) In vivo evidence for ligand-specific receptor activation in the central CRF system, as measured by local cerebral glucose utilization. Peptides 30:947-954.
30. Wong DF, Tauscher J, and Gründer G (2009) The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 34:187-203.